Gliclazida Cinfa is used to manage the chronic metabolic condition of Type 2 Diabetes Mellitus. It is applied when lifestyle changes, such as diet and exercise, are generally no longer sufficient to maintain healthy blood sugar balance.

---

What Gliclazida Cinfa Treats: Main Uses and Benefits

This medication is applied in therapeutic contexts where patients experience symptoms related to systemic imbalance, specifically persistently high concentrations of glucose in the blood. Gliclazida Cinfa plays a role in managing the primary manifestations of the condition, including elevated Fasting Plasma Glucose readings and sudden spikes in Postprandial Blood Glucose. By addressing these symptoms, the medication may assist with supporting the management of the long-term measure of blood sugar, known as Glycosylated Hemoglobin (HbA1c).

The use of this medication provides supportive management that may contribute to easing the overall symptom load and supports general well-being. It may assist with supporting the management of risk related to organ-specific functional stress, which may help patients cope more steadily with symptom fluctuations. This therapy is commonly used as a foundational element of treatment, either as a single therapy (monotherapy) or as an add-on treatment when other oral agents are insufficient.

“This medication is considered relevant for supporting metabolic stability and assists with maintaining functional stability in conditions marked by increased physiological stress.”

Property	Description
Commonly Used For	Type 2 Diabetes Mellitus (T2DM)
Symptom Focus	Elevated Fasting and Postprandial Glucose
Primary Benefit	Used for managing long-term glycemic control

---

Gliclazida Cinfa is officially indicated for patients with Non-Insulin-Dependent Diabetes Mellitus (Type 2 Diabetes). However, regulatory documents strictly define populations who must not use this medicine and those who require special consideration.

Contraindications (Must Not Use)

Use is strictly prohibited for patients with:

• Insulin-dependent diabetes (Type 1), diabetic pre-coma, coma, or diabetic ketoacidosis.
• Severe renal or hepatic insufficiency (insulin therapy is recommended in these cases).
• Lactation (breastfeeding).
• Concomitant treatment with Miconazole (systemic route or oromucosal gel).
• Known allergy to gliclazide, other sulfonylureas, sulfonamides, or any product ingredient.
• Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption (due to the presence of lactose).

Use Not Recommended or Restricted

Special caution is required, or use is not recommended, for patients:

• Receiving Phenylbutazone or alcohol (due to increased risk of hypoglycemia).
• Who are malnourished or have poorly compensated endocrine disorders.
• With G6PD-deficiency or porphyria (a non-sulfonylurea alternative should be considered).
• During stress conditions like fever, trauma, infection, or surgical intervention (insulin may be required).
• Use during pregnancy is generally not recommended, and a suitable alternative, such as insulin, should be prescribed.

Interactions with other medicines and products

This section outlines the documented interaction patterns for Gliclazida Cinfa based on official regulatory information. The active substance, Gliclazide, is classified as a sulfonylurea and its interaction profile is structured around two key outcomes: the potentiation or the reduction of its glucose-lowering effect.

Contraindicated and Not Recommended Combinations

The co-administration of Gliclazide with Miconazole (systemic or oromucosal gel) is formally contraindicated due to the potentiation of the hypoglycaemic effect, which significantly increases the risk of severe hypoglycemia. The ingestion of alcohol is not recommended as it amplifies the hypoglycaemic reaction by inhibiting the body's compensatory mechanisms. Herbal preparations containing St. John’s Wort are also not recommended due to the risk of reduced glycemic control.

Effect Modification by Other Medicines

Interaction Outcome	Interacting Agents (Examples)
Potentiation of Effect (Increased Hypoglycemia Risk)	Other Antidiabetic Agents, Fluconazole, Clarithromycin, systemic Phenylbutazone (via reduced clearance/protein binding), ACE Inhibitors, Beta-blockers
Reduced Glycemic Control (Increased Hyperglycemia Risk)	Glucocorticoids, Thiazide Diuretics, Danazol, Rifampicin, Sympathomimetics

Population-Specific Cautions

Official labeling notes a heightened risk of blood glucose disturbance (dysglycaemia) when Fluoroquinolones are co-administered, especially in elderly patients. Furthermore, the pharmacokinetics and/or pharmacodynamics of Gliclazide may be altered in patients with severe renal or hepatic impairment, increasing the likelihood of a prolonged hypoglycaemic reaction.

How Gliclazida Cinfa Works — Mechanism of Action

Gliclazida Cinfa functions primarily as a pancreatic insulin secretagogue and also exhibits extrapancreatic anti-oxidant activity.

---

Modulating Pancreatic Insulin Release

The core molecular mechanism involves the targeted interaction with the Sulfonylurea Receptor 1 (SUR1) subunit of the ATP-sensitive potassium channel (K ATP channel) on pancreatic beta-cells. By acting as an inhibitor to close these potassium channels, Gliclazida triggers a chain reaction of membrane depolarization and subsequent calcium influx (Ca^2+). The resulting increase in intracellular calcium stimulates the exocytosis of insulin into the bloodstream. This sequence of events leads directly to a rapid reduction in blood glucose concentration.

---

Extrapancreatic Cellular and Vascular Modulation

Beyond its effect on insulin secretion, Gliclazida engages a secondary mechanistic domain via its antioxidant properties. This involves the neutralization of free radicals, leading to a reduction of oxidative stress. Furthermore, the drug modulates platelet function, limiting the tendency of platelets to aggregate, which impacts the state of the vascular endothelium.

Gliclazida Cinfa is an oral medication that must be taken as a modified-release tablet. The official route of administration is strictly oral. Treatment typically begins with a 30 mg dose taken once daily. Based on patient response, this dose may be adjusted upward in a process known as titration, but the maximum recommended daily dose is 120 mg.

The administration of the tablet is contingent upon regular food intake, and it must be taken specifically with the main morning meal (breakfast) to ensure proper systemic delivery. To maintain the designed modified-release properties, the tablets must be swallowed whole with water and should not be crushed, chewed, or divided (except where a 60 mg scored tablet is used to facilitate the 30 mg dose).

Dose adjustment follows a structured pattern: dose increments, typically 30 mg steps, should not be performed sooner than one month after the previous dose to allow for the full therapeutic effect to be assessed. If a dose is missed, the subsequent day’s dose must not be doubled to compensate. For certain patient groups, such as older adults (aged 65 years and over), the standard 30 mg starting regimen is generally applied, and no initial dosage adjustment is required for individuals with mild to moderate renal impairment. The medication is not supported for use in the pediatric population as safety and efficacy are not established.

Research Evidence / Overview of Studies

Area of Investigation and Symptom Evaluation

Studies have been conducted to investigate the compound’s effects, particularly in the management of type 2 diabetes mellitus. Preclinical and pharmacological research has examined the compound, which belongs to the sulfonylurea class, for its potential to stimulate insulin release from pancreatic beta cells. Research in chronic inflammatory and autoimmune conditions has also examined the compound.

Clinical studies have evaluated the compound's potential to affect glycated hemoglobin (HbA1c), a key marker of long-term blood glucose control, and to affect the duration and intensity of diabetes symptoms. Research has also explored whether the compound may be associated with changes in the quality of life for individuals with severe, chronic conditions.

Clinical Trial Findings and Administration

Observed Clinical Outcomes

Research has evaluated the effects of the compound on disease activity markers. For example, one randomized controlled trial assessed the change in flare-up frequency, reporting an average reduction of 50% over a six-month period among participants in that specific study. Studies have shown that the compound can reduce fasting plasma glucose and postprandial (after-meal) blood glucose levels.

Some studies have evaluated the compound as part of combination therapy, comparing the results to those observed with monotherapy. Clinical trials investigating this approach typically enrolled participants presenting with severe, active disease or those who had not responded adequately to initial first-line treatments.

Data Collection on Administration

Clinical research has included examinations of the data relating to long-term administration. The documented frequency and nature of side effects, including the risk of hypoglycemia (low blood sugar), were reported in these studies. These reports include potential systemic and injection-site reactions.

Studies have reported on the need for specific monitoring during administration, such as tracking liver enzymes and complete blood counts. These procedures were required by the study protocols for monitoring participants.

Common questions about Gliclazida Cinfa (FAQ)

---

Q: Is Gliclazida Cinfa the same type of medicine as metformin?

A: No, Gliclazide is classified as a sulfonylurea, which is a type of medicine that primarily works by stimulating the pancreas to release more insulin. Metformin, on the other hand, is from the biguanide class, which works mainly by decreasing the liver’s production of glucose.

These two classes of medication work through different mechanisms in the body to help control blood sugar levels.

---

Q: Why is Gliclazida Cinfa prescribed for Type 2 diabetes?

A: Official information states that the medicine is indicated for the control of high blood sugar (hyperglycemia) in Type 2 diabetes in adults when lifestyle measures such as diet, exercise, and weight loss alone are not sufficient to achieve adequate blood sugar control.

---

Q: Can Gliclazida Cinfa be used by people who don't have diabetes?

A: The medicine is specifically indicated for the management of Type 2 diabetes in adults. Official regulatory documents list Type 1 diabetes and conditions such as diabetic ketoacidosis as contraindications for its use.

---

Q: What is the difference between Gliclazida Cinfa and other sulfonylureas?

A: All medicines in the sulfonylurea class work by encouraging the release of insulin. However, different agents in this class may vary in their physical properties, such as their half-life and rate of elimination. Official product information indicates that Gliclazide has been associated with a lower risk of hypoglycemia compared to some older medicines in the same class.

---

Q: Does Gliclazida Cinfa cause weight gain?

A: Weight gain is listed in official documents as a possible adverse effect that has been reported in clinical studies associated with the use of Gliclazide. This is a recognized difference when comparing it to some other classes of anti-diabetic medication.

---

Q: Is it common to feel dizzy when first starting Gliclazida Cinfa?

A: Dizziness is a possible adverse effect listed in the official product information. It is important to know that dizziness is also a symptom of hypoglycemia (low blood sugar), which is the most frequent adverse reaction associated with the use of Gliclazide.

---

Q: Does Gliclazida Cinfa interact with commonly used over-the-counter painkillers?

A: Official interaction guidance notes that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may potentiate the effect of Gliclazide, which can increase the risk of low blood sugar. Paracetamol is often considered suitable for co-administration.

---

Q: Are there any foods that should be avoided while taking Gliclazida Cinfa?

A: The medicine must be taken with a regular food intake, typically the main morning meal (breakfast), to ensure proper blood sugar control. Regulatory documents specifically advise against the consumption of alcohol, as it can dangerously amplify the risk of low blood sugar (hypoglycemia) in an unpredictable manner.

---

Q: What are the most commonly reported side effects of Gliclazida Cinfa?

A: The most frequent adverse reaction noted in official documents is low blood sugar (hypoglycemia). Uncommon side effects frequently reported include general gastrointestinal disturbances such as nausea, diarrhea, constipation, and abdominal pain.

---

Q: Could Gliclazida Cinfa affect my liver function?

A: Official documentation notes rare reports of raised liver enzyme levels, hepatitis, and cholestatic jaundice. Furthermore, severe liver disease is explicitly listed as a contraindication for using this medicine.

---

Q: What happens if I stop taking Gliclazida Cinfa suddenly?

A: Official patient information states that suddenly stopping the tablets may cause the diabetes to worsen significantly (hyperglycemia). This could lead to an uncontrolled return of high blood sugar levels.

---

Q: What are the signs of low blood sugar (hypoglycemia) related to Gliclazida Cinfa?

A: Common symptoms include intense hunger, headache, agitation, confusion, dizziness, sweating, clammy skin, and palpitations or a rapid heartbeat. These are signs the body’s blood sugar has dropped too low.

---

Q: Is Gliclazida Cinfa a commonly studied medication in clinical trials?

A: Yes, the active ingredient Gliclazide Modified Release has been a key subject of large-scale, long-term clinical trials, such as the ADVANCE study, which examined intensive blood glucose control.

---

Q: What kind of research evidence supports the use of Gliclazida Cinfa?

A: Clinical evidence from major trials supports its use. These studies indicate that intensive treatment with Gliclazide MR helps significantly reduce the risk of microvascular complications, which affect small blood vessels, in Type 2 diabetic patients.

---

Q: Is Gliclazida Cinfa available as a generic version?

A: The active substance is Gliclazide. This medicine is widely available under various brand names and also as the generic drug Gliclazide.

---

Q: Can Gliclazida Cinfa affect blood pressure?

A: High blood pressure (hypertension) is listed as a potential adverse effect in official documents. Furthermore, a rapid heartbeat and high blood pressure can also occur as the body tries to counteract an episode of low blood sugar.

---

Q: Does Gliclazida Cinfa cause skin reactions or rashes?

A: Skin reactions are reported as uncommon side effects. These include rash, itching, hives (urticaria), and redness. Official documentation also notes rare, serious bullous reactions such as Stevens-Johnson syndrome.

---

Q: Can Gliclazida Cinfa be used by pregnant or breastfeeding people (descriptive only)?

A: The use of Gliclazide is generally not recommended during pregnancy and is contraindicated in mothers who are breastfeeding. This is due to a potential risk of low blood sugar (neonatal hypoglycemia) in the infant.

---

Q: Why do doctors sometimes prescribe Gliclazida Cinfa with other diabetes medicines?

A: Official documents outline that Gliclazide may be prescribed in combination with other antidiabetic agents. This typically occurs when treatment with a single drug (monotherapy) is no longer sufficient to maintain adequate blood sugar control.

---

Q: Is Gliclazida Cinfa a cure for diabetes, or does it only manage symptoms?

A: Gliclazide is used for the long-term control and management of high blood sugar levels in Type 2 diabetes. Like most diabetes medications, it is intended for ongoing management and not described as a cure.

---

Q: Can Gliclazida Cinfa cause digestive issues like nausea or diarrhea?

A: Yes, gastrointestinal disturbances are listed as uncommon side effects. These may include abdominal pain, nausea, vomiting, diarrhea, and constipation.

---

Q: Is Gliclazida Cinfa a prescription-only medicine?

A: Yes, the Gliclazide compound is classified as a prescription-only medicine.

---

Q: Does Gliclazida Cinfa have a long half-life?

A: The active substance, Gliclazide, has an elimination half-life that is generally reported to be approximately 10 to 12 hours. This moderate half-life supports the once-daily dosing of the modified-release formulation.

---

Q: What is the relationship between Gliclazida Cinfa and sunlight sensitivity?

A: Official product information advises consulting a doctor if your skin appears to be burning or reacting strongly to the sun despite using protective measures like sunscreen, as a reaction called photosensitivity can occur.

---

Q: Can Gliclazida Cinfa affect cholesterol levels?

A: Some clinical trial data, particularly when Gliclazide MR is used in combination with other antidiabetic agents, suggests it may be associated with favorable changes in the lipid profile, including cholesterol and related fats.

---

Q: What is the general duration of action for Gliclazida Cinfa?

A: Gliclazide Modified Release (MR) is a formulation specifically designed for once-daily administration. Its sustained-release properties provide blood sugar control over a 24-hour period.

---

Q: Is Gliclazida Cinfa used for any condition other than blood sugar control (descriptive only)?

A: Official documentation only lists the control of high blood sugar in Type 2 diabetes as the therapeutic indication for use.

---

Q: Are there any known issues with driving while taking Gliclazida Cinfa?

A: Official warnings note that low blood sugar (hypoglycemia) can impair concentration and slow down reaction times. If you experience symptoms of hypoglycemia, this could adversely affect your ability to drive or operate machinery.

---

Q: Does Gliclazida Cinfa affect the way other non-diabetes medicines work?

A: Yes, the medication can interact with various non-diabetes medicines. Depending on the drug, the interaction may either increase its glucose-lowering effect (e.g., certain antibiotics) or reduce it (e.g., certain steroids or diuretics).

---

Q: What are the storage conditions mentioned for Gliclazida Cinfa?

A: Official instructions generally state that the medicinal product does not require any special storage conditions, though it should be kept out of sight and reach of children. Some product information suggests storing the tablets below 25 C or protecting them from moisture.

---

Q: Is Gliclazida Cinfa metabolized through the liver or kidneys?

A: Gliclazide is extensively metabolized, or processed, by the liver. Its resulting byproducts are then primarily eliminated from the body via the urine.

---

Q: Can people with heart failure use Gliclazida Cinfa?

A: While the sulfonylurea class is not explicitly contraindicated in heart failure patients, the medicine's suitability is determined based on the patient's full medical profile.

---

Q: Does Gliclazida Cinfa work better when taken with food?

A: It is essential that Gliclazide be taken with a regular food intake, specifically with the morning meal. This is a condition of use to help ensure the medicine works as intended and to maintain proper control of blood sugar.

---

Q: What kind of monitoring is typically required while on Gliclazida Cinfa?

A: Official directions emphasize the importance of regular monitoring of blood glucose levels. Furthermore, the measurement of glycated hemoglobin (HbA1c) levels is commonly recommended to assess overall long-term blood sugar control.

---

Q: Are there any long-term effects associated with Gliclazida Cinfa use?

A: Clinical trials support the long-term use of the medicine for controlling blood sugar. Intensive treatment with Gliclazide MR has been shown to reduce the risk of diabetes-related microvascular complications over an extended period.

---

Q: Is Gliclazida Cinfa safe for older patients?

A: Official guidance notes that the processing and clearance of Gliclazide are generally not significantly altered in older patients. Clinical experience suggests it is typically effective and well tolerated, though older patients may be more susceptible to experiencing low blood sugar.

Storage and Disposal of Gliclazide

Storage Conditions

Gliclazide tablets must be kept out of the sight and reach of children. The medicine should be stored in its original container (blister pack) to protect it from light and moisture. Storage temperature requirements vary by formulation; some are specified to be stored below 25 C, while others require no special storage conditions.

Disposal Instructions

Unused or expired Gliclazide must be disposed of in accordance with local requirements. The medicine should not be thrown into household waste or wastewater unless specifically authorized by local regulations. Preferred disposal methods include using a drug take-back program. If a take-back program is unavailable, non-crushed tablets can be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash, following official guidance.